Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs Monoclonal Antibody Based Products - Global Strategic Business Report
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

Monoclonal Antibody Based Products - Global Strategic Business Report

DateAug, 2006
Pages487
Price / format€2611 / Electronic
€2611 / Hard Copy

€2 611 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 This report analyzes the worldwide markets for Monoclonal Antibody Based Products in Millions of US$. The major product segments and application areas analyzed are Therapeutics, and Diagnostics, especially for cancer. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of world. Annual forecasts are provided for each region and product segment for the period of 2000 through 2010. The report profiles 99 companies including many key and niche players worldwide such as Amgen, BD Biosciences, Biogen Idec Inc., Biotest AG, Cambridge Antibody Technology , Dendreon Corporation, Elan Corporations Plc, Eli Lilly, Genentech, Inc., Guildhay, Human Genome Sciences, ICOS, Immunomedics, Johnson & Johnson , Centocor, Medarex Inc, Medlmmune Inc, PDL BioPharma, Schering-Plough Corporation, Strategic BioSolutions, UCB Group, and Wyeth Pharmaceuticals. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on "Enquire before buying"








Table of contents:
 MONOCLONAL ANTIBODY BASED PRODUCTS
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Therapeutics I-3
Cancer I-4
Other Therapeutic Mabs I-4
Diagnostics I-4
Cancer I-4
Other Diagnostic MAbs I-4


II. EXECUTIVE SUMMERY

1. Industry Overview II-1
World MAb-Based Products Market: A Profile II-1
Genomics Research Leads Way to New Monoclonal Antibodies II-1
Bright Outlook for MAbs II-2
Current and Future Analysis II-2
Regional Perspective II-2
Product Segment Perspective II-2
Competitive Scenario II-3
Table 1: Monoclonal Antibody Based Products Market (2004):
Percentage Breakdown of Leading Manufacturers by Sales for
Genentech, Johnson & Johnson, Roche, Abbott, MedImmune,
Schering Plough, Eli Lilly, and Others (includes
corresponding Graph/Chart) II-3

Table 2: Monoclonal Antibody Based Products Market (2004):
Percentage Breakdown of Leading Drugs by Sales for Remicade,
Rituxan, Herceptin, Synagis, Humira, Avastin, ReoPro,
Erbitux, Xolair, and Others (includes corresponding Graph/
Chart) II-4
Therapeutic Antibodies in the Market: 2004 II-4
Drug Developers Trying to Break the Shackles II-5
Rituximab Vs. Epratuzumab II-5
A Revolution Not too Far II-5
Milestones in Development of MAbs II-5
Focus on Unmet Medical Needs in the Emerging Markets II-5

2. Industry Analysis II-6
Trends and Issues II-6
Shift Towards Humanized and Fully Human Antibodies II-6
Ageing Baby Boomers Spur MAbs Growth II-6
Booming Period for Therapeutic Antibodies II-6
Partnerships and Collaborations Spark Increase in Profit
Margins II-7
High Costs Impede MAbs Penetration II-7
Opportunities in Technology Development II-7
Worldwide Select Antibody Technology Companies II-8
Increasing Demand for Protein A in MAb Manufacturing II-8
Economic and Humane Concerns Limit Antibody Production in Mice II-8
FCA- A Major Cause for Discomfort in Mice II-8
Widespread Utilization of MAb Technology in Pharmaceuticals
Market II-9

3. Product Overview II-10
Immune System: Natural Defenders II-10
Human Antibodies II-10
Antibodies Offer Natural Immunity II-10
Induction of The Immune Process II-10
Mechanism of Action II-10
Polyclonal and Monoclonal Antibodies II-11
Production of Monoclonal Antibodies II-11
Traditional Methods II-11
The Hybridoma Technology II-11
Separation and Purification of Monoclonals II-11
Factors Impacting Production of MAbs II-12
Types of Monoclonal Antibodies II-12
Table 3: Monoclonal Antibody Market by Product Type (2004 &
2010): Percentage Breakdown by Sales for Chimeric,
Humanized, Fully Human, Fragment, and Conjugated (includes
corresponding Graph/Chart) II-12
Murine Monoclonal Antibodies II-12
Humanized Antibodies/ CDR Grafted Antibodies II-13
Murine Vs Human Monoclonal Antibodies II-13
Chimeric Antibodies: Show Lesser Antigenicity II-14
Fully Human Antibodies II-14
Bispecific Antibodies II-14
Certain Limitations Do Exist II-14
Advantages of MAbs II-15
Advantages and Limitations of MAb Technologies II-15

4. Diagnostic Applications of Monoclonal Antibodies II-16
Monoclonal Antibody Based Diagnostics II-16
Immunodiagnostics II-16
Monoclonals Used as Targeting Agents II-16
Radio labeled Monoclonal Antibodies for Diagnostic Imaging II-16
The Pros and Cons of MAb-Based Immunoconjugates II-17
Cytogen: The First to Introduce A Monoclonal Antibody- based
Cancer Agent II-17
NeoProbe’s Radioimmunogzuided Surgery II-17
Mechanism of Working II-18
Cancer II-18
A Historical Overview II-18
Initial Hiccups II-18
Tumor Markers II-19
Pregnancy/Fertility Testing II-19

5. Monoclonal Antibody-Based Therapeutics For Cancer II-20
Evolution of Therapeutic Antibody Products II-20
Advantages of Therapeutic Monoclonal Antibodies II-20
Current Scenario in Monoclonal Antibody Therapeutics Market II-20
Table 4: Monoclonal Antibody Market by Therapy Area (2004 &
2010): Percentage Breakdown by Sales for Oncology,
Arthritis, Immune & Inflammatory Disorders, Infectious
Diseases, Cardiovascular, Respiratory, Ophthalmology, and CNS
(includes corresponding Graph/Chart) II-21
Cancer Therapeutics II-21
Monoclonal Antibodies Offer Hope Against Cancer II-21
Antibody Therapies for Cancer II-21
Cancer: A Serious Issue and Plaguing Illness Worldwide II-22
Status of MAbs for Cancer in 2004 II-22
Breast Cancer: The Most Common Form of Cancer in American Women II-23
Breast Cancer
Treatment Options II-23
Monoclonal Antibodies Against NHL II-23
Monoclonal Antibodies Against Ovarian Cancer II-24
MAb Immunotherapy
Effective for Residual Ovarian Cancer II-24
Melanoma II-24
MAbs Linked With Toxins Found Effective II-25
Immunologic Effector Functions II-25
Colorectal Cancer: Rising Incidence II-25
Panorex: The First Cancer Therapeutic in the Market II-25
Myeloid Leukemia II-25
Prostrate Cancer II-26
Cancers of the Immune System II-26
Non-Hodgkin’s Lymphoma II-26
Monoclonal Antibodies Attack Residual Cancer II-27
What the Future Holds II-27

6. Other Therapeutic Monoclonal Antibodies II-28
Therapeutic Monoclonal Antibody Drugs and Applications II-28
MAbs used in Clinical Field II-28
Inflammation Therapeutics II-28
Inflammation II-28
Asthma: A Chronic Affliction II-29
CGP 51 901 To Treat Asthma II-29
Autoimmune Diseases II-29
What Goes Wrong II-29
Intervention Better Than Prevention II-30
Some Autoimmune Diseases II-30
Multiple Sclerosis II-30
Crohn’s Disease II-31
Rheumatoid Arthritis II-31
Organ Transplantation II-31
Biology of Transplantation II-31
Types of Transplants II-32
Autografts II-32
Syngeneic Transplants II-32
Allografts II-32
Xenografts II-32
Follow-up Treatment II-32
Products to Counter Rejection II-32
OKT3: A Monoclonal Already in the Market II-33
Infectious Diseases II-33
Sepsis II-33
A Rapid Process II-33
Gram Negative Bacteria are the Causative Agents II-33
A Retrospect II-34
Monoclonal Antibodies and Septic Shock II-34
What is HIV/AIDS II-35
What is AIDS? II-35
Global Statistics II-35
HIV/AIDS Testing II-35
Monoclonal Antibodies and HIV II-35
Cardiovascular II-36
Cardiovascular Diseases are Fatal II-36
Treatment Options II-36
Causes of Cardiovascular Diseases II-36
ReoPro: The Solution to the Problem II-37

7. Regulation Impacting The Industry II-38
Regulations in the U.S II-38
Approval: A Laborious Process II-38
Clinical Trials II-38
Orphan Drug Status II-39

8. Contract Manufacturing II-40
Outlook II-40

9. Research and Development Activities II-41
Rituxan and Herceptin from Genentech II-41
FuCell hybridomas II-41
Test-tube MAbs/ Phase Display Library II-41
Rituxan for Cancer Treatment II-41
GenMAb Develops Fully Human Antibodies II-42
Protein Design Labs Licenses Trioma II-42
Protein Design Labs’ Innovative Technology II-42

10. Product Launches and Developments II-43
Biotest AG and AERES Biomedical Develop BT-062 II-43
Genentech Launches Avastin II-43
Biotest Unveils Intratect® II-43
Genentech Introduces Xolair II-43
Genentech Unveils Raptiva II-43
Corixa Presents BEXXAR II-43
IGEN Launches Monoclonal Antibody Therapies II-44
MAb Against Pseudomonas Aeruginosa II-44
Wyeth Introduces Mylotarg II-44
Generics Launches Herceptin II-44

11. Recent Industry Activity II-45
Merck to Acquire Abmaxis II-45
Micromet to Merge with CancerVax II-45
PharmAthene to Merge Operations with SIGA II-45
FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen II-45
LSP Acquires Global License for Monoclonal Antibodies
fromLudwig Institute II-46
Seattle Genetics in Agreement with Laureate to Manufacture
Monoclonal Antibody Drug Candidates II-46
EU Grants Orphan Drug Designation to GPC’s Anticancer
Monoclonal Antibody II-47
Laureate Collaborates with Bradmer on Neuradiab Monoclonal
Antibody for Cancer Treatment II-47
Amgen Takes Over Abgenix II-47
Celera and Medarex in Strategic Alliance for Developing Human
Monoclonal Antibody Therapeutics II-47
UCB Collaborates with Immunomedics II-48
Crucell Collaborates with DSM for Monoclonal Antibody
Licensing Business II-48
Roche Licenses Rabbit Monoclonal Antibody Technology from
Epitomics II-48
BioGenex Receives FDA Pre-Market Approval for InSite
Monoclonal Antibody II-49
Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal
Antibody II-49
XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin
Monoclonal Antibodies II-49
HGS Bags Two-Phase Contract for ABthrax MAb from the US
Government II-50
Medarex and PharmAthene Receive Funding for Development of
Valortim II-50
UCB Collaborates with Millenium II-50
MorphoSys Acquires Two Antibody Technology Companies II-50
Tanabe Seiyaku and Remicade Sign Addendum II-50
Abgenix Receives Royalty from Human Genome II-51
Amgen Acquires Tularik II-51
Sunesis Pharmaceuticals Collaborates with Biogen Idec II-51
H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM
Biologics II-51
EMBL and Abnova Inks Collaboration Agreement II-51
AstraZeneca and CAT in Five-Year Strategic Alliance for
Monoclonal Antibody Research II-52
UCB Acquires Celltech II-52
ImmunoGen Signs Licensing Agreement with Biogen II-52
Lonza Inks MAbs Manufacturing and Supply Agreement with
NovImmune II-52
Avanir and Peregrine Sign License Agreement II-52
BioVest Concludes Agreement with Bioventix II-53
Roche to Set Up Two Manufacturing Facilities in Switzerland II-53
XTL Biopharm Bags European patent for Human Monoclonal Anti Body II-53
MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials II-53
Health Canada Approves HUMIRA II-53
CAT Signs Licensing Agreement with Micromet II-54
CAT Enters into Agreement with Genzyme II-54
Medarex and Avlon Enter into Agreement II-54
Micromet, Enzon and CAT Sign Cross-License Agreement II-54
Xerion and CAT Enter into Agreement II-54
Genetastix and Nissho Enter into Agreement II-54
InNexus and Corixa Enter into Agreement II-55
Abbott Collaborates with LigoCyte II-55
CAT Acquires Drug Royalty Corporation II-55
CAT and Amrad Join Hands for Research II-55
IDECs Receives FDA Approval for Zevalin II-55
Medarex Enters into Research Alliance with Seattle Genetics II-55
Dow, Epicyte and Centocor Join Forces to Develop Monoclonal
Antibody II-56
Eos, Medarex and Biosite in Alliance for Cancer Treatment II-56
Imgenex forms Alliance with GMO II-56
CAT and Elan Enter into Strategic Alliance II-56
Bioinvent International Enters into Agreement with Novo
Nordisk for Drug Discovery Research II-56
Epicyte and Dow Chemical Enter into Agreement II-57
Rockland Announces the Completion of Laboratory Expansion II-57
Roche’s MAbThera Receives Approval in Japan II-57
Aviva Launches Manufacturing and Marketing Operations II-57
ICOS and Seattle Enters into Joint Development and
Manufacturing Agreement II-57
Medarex and Corixa Team-up to Develop Human Monoclonal
Antibodies II-57
Taisho Enters into Research Alliance with IDEC II-57
PDL Signs Agreement with InterMune II-57
ProMetic Signs Agreement with Integrated Protein II-58
Medarex Signs Agreement with ZynloGenetics II-58
CAT Joins Hands with GD. Searle II-58
Medarex and MedImmune Enter into Antibody Research Agreement II-58
Lonza Signs Agreement with ImClone Systems II-58
MedImmune and Alkermes Enter into Agreement II-58
GTC and Abgenix Enter into Production Agreement II-59
Genzyme Transgenics Expands Agreement with Centocor II-59
PDL and InterMune Enter into an Agreement II-59

12. Focus on Select Global Players II-60
Amgen (US) II-60
BD Biosciences (US) II-60
Biogen Idec Inc (US) II-61
Biotest AG (Germany) II-61
Cambridge Antibody Technology (UK) II-61
Dendreon Corporation (US) II-62
Elan Corporations Plc (Ireland) II-62
Eli Lilly (US) II-63
Genentech, Inc. (USA) II-63
Guildhay (UK) II-63
Human Genome Sciences (US) II-64
ICOS (US) II-64
Immunomedics (US) II-65
Johnson & Johnson (US) II-65
Centocor (US) II-65
Medarex, Inc. (US) II-66
MedImmune, Inc. (US) II-66
PDL BioPharma (US) II-66
Schering-Plough Corporation (US) II-67
Strategic BioSolutions (US) II-67
UCB Group (Belgium) II-67
Wyeth Pharmaceuticals (US) II-68

13. Global Market Perspective II-69
Table 5: World Recent Past, Current & Future Market Analysis
for Monoclonal Antibody Based Products by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and
Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-69

Table 6: World 10-Year Perspective for Monoclonal Antibody
Based Products by Geographic Region
Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Rest of World Markets for Years 2000,
2005 & 2010 (includes corresponding Graph/Chart) II-69

Table 7: World Recent Past, Current & Future Market Analysis
for Therapeutic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-70

Table 8: World Recent Past, Current & Future Market Analysis
for Therapeutic Monoclonal Antibody Based Products by Segment

Cancer and Other Therapeutics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-70

Table 9: World 10-Year Perspective for Therapeutic Monoclonal
Antibody Based Products by Geographic Region
Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia-
Pacific, and Rest of World Markets for Years 2000, 2005 &
2010 (includes corresponding Graph/Chart) II-71

Table 10: World 10-Year Perspective for Therapeutic
Monoclonal Antibody Based Products by Segments
Percentage
Breakdown of Dollar Sales for Cancer and Other Therapeutics
Markets for Years 2000, 2005 & 2010 II-71

Table 11: World Recent Past, Current & Future Market Analysis
for Cancer Therapeutic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-72

Table 12: World 10-Year Perspective for Cancer Therapeutic
Monoclonal Antibody Based Products by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe Asia-Pacific, and Rest of World Markets for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-72

Table 13: World Recent Past, Current & Future Market Analysis
for Other Therapeutic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-73

Table 14: World 10-Year Perspective for Other Therapeutic
Monoclonal Antibody Based Products by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe Asia-Pacific, and Rest of World Markets for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-73

Table 15: World Recent Past, Current & Future Market Analysis
for Diagnostic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-74

Table 16: World Recent Past, Current & Future Market Analysis
for Diagnostic Monoclonal Antibody Based Products by Segments

Cancer and Other Diagnostics Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-74

Table 17: World 10-Year Perspective for Diagnostic Monoclonal
Antibody Based Products by Geographic Region
Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia
-Pacific, and Rest of World Markets for Years 2000, 2005 &
2010 (includes corresponding Graph/Chart) II-75

Table 18: World 10-Year Perspective for Diagnostic Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Cancer and Other Diagnostics Markets for
Years 2000, 2005 & 2010 II-75

Table 19: World Recent Past, Current & Future Market Analysis
for Cancer Diagnostic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-76

Table 20: World 10-Year Perspective for Cancer Diagnostic
Monoclonal Antibody Based Products by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe Asia-Pacific, and Rest of World Markets for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-76

Table 21: World Recent Past, Current & Future Market Analysis
for Other Diagnostic Monoclonal Antibody Based Products by
Geographic Region
US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-77

Table 22: World 10-Year Perspective for Other Diagnostic
Monoclonal Antibody Based Products by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe Asia-Pacific, and Rest of World Markets for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-77


III. MARKET

1. The Untied States III-1
A.Market Analysis III-1
Global Hub of MAbs III-1
Approved Therapeutic Antibodies in the US as of 2004 III-1
New Heights f or US Cancer Therapeutics III-2
Focus on Key Players III-2
Abgenix III-2
BD Biosciences III-3
Biogen Idec. III-4
Dendreon Corporation III-4
Eli Lilly III-4
Genentech, Inc. III-4
Human Genome Sciences III-5
ICOS III-5
Immunomedics III-5
Johnson & Johnson III-6
Centocor III-6
Medarex, Inc. III-7
MedImmune, Inc III-7
PDL BioPharma III-7
Schering-Plough Corporation III-8
Strategic BioSolutions III-8
Wyeth Pharmaceuticals III-8
Product launches III-9
Strategic Developments III-10
Historic Developments III-18
B.Market Analytics III-19
Table 23: US Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment
Therapeutics
(Cancer and Others), and Diagnostics (Cancer and Others)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-19

Table 24: US 10-Year Perspective for Monoclonal Antibody
Based Products by Segment
Percentage Breakdown of Dollar
Sales for Therapeutics (Cancer and Others), and Diagnostics
(Cancer and Others) Markets for 2000, 2005 & 2010 III-19

2. Canada III-20
A.Market Analysis III-20
Strategic Developments III-20
B.Market Analytics III-21
Table 25: Canadian Recent Past, Current & Future Analysis
for Monoclonal Antibody Based Products by Segment -
Therapeutics (Cancer and Others), and Diagnostics (Cancer
and Others) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-21

Table 26: Canadian 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-21

3. Japan III-22
A.Market Analysis III-22
Strategic Developments III-22
B.Market Analytics III-23
Table 27: Japanese Recent Past, Current & Future Analysis
for Monoclonal Antibody Based Products by Segment -
Therapeutics (Cancer and Others), and Diagnostics (Cancer
and Others) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010,
(includes corresponding Graph/Chart) III-23

Table 28: Japanese 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-23

4. Europe III-24
A.Market Analysis III-24
Biotechnology and Pharmacy Research III-24
Monoclonal Antibody Based Products Market in Europe III-24
Trends in Select European Countries III-24
Approved Therapeutic Antibodies in Europe as of 2004 III-24
Historic Development III-25
B.Market Analytics III-25
Table 29: European Recent Past, Current & Future Analysis
for Monoclonal Antibody Based Products by Geographic Region

France, Germany, Italy, UK & Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-25

Table 30: European Recent Past, Current & Future Analysis
for Monoclonal Antibody Based Products by Segment -
Therapeutics (Cancer and Others), and Diagnostics (Cancer
and Others) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-26

Table 31: European 10-Year Perspective for Monoclonal
Antibody Based Products by Geographic Region -Percentage
Breakdown of Dollar Sales for France, Germany, Italy, the
UK, and Rest of Europe for Years 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-26

Table 32: European 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-27

4a. France III-28
Market Analysis III-28
Table 33: French Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics
(Cancer and Others), and Diagnostics (Cancer and Others)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-28

Table 34: French 10-Year Perspective for Monoclonal Antibody
Based Products by Segment
Percentage Breakdown of Dollar
Sales for Therapeutics (Cancer and Others), and Diagnostics
(Cancer and Others) Markets for 2000, 2005 & 2010 III-29

4b. Germany III-30
A.Market Analysis III-30
Biotest AG- A Key Player III-30
Product Launches III-30
Strategic Developments III-31
B.Market Analytics III-33
Table 35: German Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics
(Cancer and Others), and Diagnostics (Cancer and Others)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-33

Table 36: German 10-Year Perspective for Monoclonal Antibody
Based Products by Segment
Percentage Breakdown of Dollar
Sales for Therapeutics (Cancer and Others),and Diagnostics
(Cancer and Others) Markets for 2000, 2005 & 2010 III-33

4c. Italy III-34
Market Analysis III-34
Table 37: Italian Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics
(Cancer and Others), and Diagnostics (Cancer and Others)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-34

Table 38: Italian 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-35

4d. The United Kingdom III-36
A.Market Analysis III-36
Focus on Key Players III-36
Cambridge Antibody Technology (CAT) III-36
Guildhay III-36
Strategic Developments III-37
B.Market Analytics III-39
Table 39: UK Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics
(Cancer and Others), and Diagnostics (Cancer and Others)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-39

Table 40: UK 10-Year Perspective for Monoclonal Antibody
Based Products by Segment
Percentage Breakdown of Dollar
Sales for Therapeutics (Cancer and Others), and Diagnostics
(Cancer and Others) Markets for 2000, 2005 & 2010 III-39

4e. Rest of Europe III-40
A.Market Analysis III-40
Key Players III-40
Elan Corporations Plc (Ireland) III-40
UCB Group (Belgium) III-40
Strategic Developments III-41
B.Market Analytics III-43
Table 41: Rest of Europe Market for Monoclonal Antibody
Based Products
Recent Past, Current & Future Analysis by
Product Segment for Therapeutics (Cancer and Others), and
Diagnostics (Cancer and Others) Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-43

Table 42: Rest of Europe 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-43

5. Asia-Pacific III-44
A.Market Analysis III-44
Indian Market III-44
Strategic Developments III-44
B.Market Analytics III-45
Table 43: Asia-Pacific Market for Monoclonal Antibody Based
Products
Recent Past, Current & Future Analysis by
Product Segment for Therapeutics (Cancer and Others), and
Diagnostics (Cancer and Others) Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-45

Table 44: Asia-Pacific 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others), and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-46

6. Rest of World III-47
Market Analysis III-47
Table 45: Rest of World Market for Monoclonal Antibody
Based Products
Recent Past, Current & Future Analysis by
Product Segment for Therapeutics (Cancer and Others), and
Diagnostics (Cancer and Others) Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-47

Table 46: Rest of World 10-Year Perspective for Monoclonal
Antibody Based Products by Segment
Percentage Breakdown of
Dollar Sales for Therapeutics (Cancer and Others),and
Diagnostics (Cancer and Others) Markets for 2000, 2005 &
2010 III-48


IV. COMPETITION

1. Abbott Laboratories (USA) IV-1
Table 47: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ billion) IV-3

Table 48: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-3
2. Abnova Corporation (Taiwan) IV-10
3. American Diagnostica, Inc. (USA) IV-11
4. American Qualex (USA) IV-13
5. Amgen, Inc. (USA) IV-14
Table 49: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-15

Table 50: Annual Sales Analysis: 2004-2005 (In US$
million) IV-15

Table 51: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-15
6. Antibodies, Inc. (USA) IV-18
7. Avanir Pharmaceuticals (USA) IV-20
Table 52: Nine Months Sales Analysis: 2005-2006 (Nine
Months ended, June) (In US$ million) IV-21

Table 53: Nine Months Sales Analysis by Quarter: 2005-
2006 (Nine Months ended, June) (In US$ million) IV-21

Table 54: Nine Months Sales Analysis by Business
Segment: 2005-2006 (Nine Months ended, June) (In US$
million) IV-21

Table 55: Annual Sales Analysis: 2004-2005 (In US$
million) IV-21

Table 56: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-22

Table 57: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-22
8. Beckman Coulter, Inc. (USA) IV-24
Table 58: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-28

Table 59: Annual Sales Analysis: 2004-2005 (In US$
million) IV-28

Table 60: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-28

Table 61: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-28
9. Becton Dickinson and Company (USA) IV-31
Table 62: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-33

Table 63: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In US$ million) IV-33

Table 64: Half Yearly Sales Analysis by Segment: 2005-
2006 (H1) (In US$ million) IV-33

Table 65: Annual Sales Analysis: 2004-2005 (In US$
million) IV-33

Table 66: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-33

Table 67: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-34

Table 68: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-34
BD Biosciences (USA) IV-39
10. Binding Site Ltd. The (UK) IV-56
11. Bioclone Australia Pty., Ltd. (Australia) IV-59
12. Biogen Idec, Inc. (USA) IV-60
Table 69: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ billion) IV-61

Table 70: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-61

Table 71: Quarterly Sales Analysis: 2004-2005 (In US$
billion) IV-61
13. Biogenex Laboratories, Inc. (USA) IV-67
14. BioInvent International AB (Sweden) IV-70
15. Biomйrieux SA (France) IV-72
Table 72: Annual Sales Analysis: 2004-2005 (In Ђ
million) IV-73
Biomerieux, Inc. (USA) IV-76
16. Biomira, Inc. (Canada) IV-79
Biomira USA, Inc. (USA) IV-80
17. Biosource International, Inc. (USA) IV-81
18. Biotest AG (Germany) IV-82
19. Bioventix (UK) IV-83
20. Bradmer Pharmaceuticals, Inc. (Canada) IV-84
21. Calbiochem (USA) IV-85
22. Cambrex Corporation (USA) IV-88
Table 73: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-90

Table 74: Quarterly Sales Analysis: 2005-2006 (H1) (In
US$ million) IV-90

Table 75: Annual Sales Analysis: 2004-2005 (In US$
million) IV-90

Table 76: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-90
23. Cambridge Antibody Technology (UK) IV-95
Table 77: Half Yearly Sales Analysis: 2004-2005 (H1)
(In Ј million) IV-95
24. Capricorn Products, Inc. (USA) IV-97
25. Celera Genomics Group (USA) IV-98
26. Celgene Corporation (USA) IV-100
Table 78: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-101

Table 79: Annual Sales Analysis: 2004-2005 (In US$
million) IV-101

Table 80: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-101

Table 81: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-102

Table 82: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-102
27. Chemicon International, Inc. (USA) IV-105
28. Crucell NV (The Netherlands) IV-110
Table 83: First Quarter Sales Analysis: 2005-2006 (Q1)
(In million) IV-111

Table 84: Annual Sales Analysis: 2004-2005 (In Ђ
million) IV-111

Table 85: Annual Sales Analysis by Geographic Region:
2004-2005 (In Ђ million) IV-111
Berna Biotech AG (Switzerland) IV-116
29. Cytogen Corporation (USA) IV-118
Table 86: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-118
Table 87: Half Yearly Sales Analysis by Business
Operations: 2005-2006 (H1) (In US$ million) IV-119
Table 88: Annual Sales Analysis: 2004-2005 (In US$
million) IV-119

Table 89: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-119

Table 90: Annual Sales Analysis by Business Operations:
2004-2005 (In US$ million) IV-119
30. Dakocytomation Denmark A/S (Denmark) IV-123
Dakocytomation (USA) IV-125
Dakocytomation Diagnosticos SA (Spain) IV-126
31. Dendreon Corporation (USA) IV-128
Table 91: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-128

Table 92: Annual Sales Analysis: 2004-2005 (In US$
million) IV-128

Table 93: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-129
32. DiaSorin SpA (Italy) IV-130
Diasorin, Inc. (USA) IV-131
33. DRG International, Inc. (USA) IV-133
DRG Instruments GmbH (Germany) IV-135
DRG Medtek SP Z o o (Poland) IV-136
34. DSM Biologics (The Netherlands) IV-137
35. ELAN Corporation PLC (Ireland) IV-138
Table 94: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-139

Table 95: Annual Sales Analysis: 2004-2005 (In US$
million) IV-139

Table 96: Annual Sales Analysis By Segment: 2004-2005
(In US$ million) IV-139

Table 97: Annual Sales Analysis By Geographic Region:
2004-2005 (In US$ million) IV-139
36. Eli Lilly and Company (USA) IV-141
Table 98: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ billion) IV-143

Table 99: First Quarter Sales Analysis by Business
Segment: 2005-2006 (Q1) (In US$ billion) IV-143
Table 100: First Quarter Sales Analysis by Product
Segment: 2005-2006 (Q1) (In US$ billion) IV-143
Table 101: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-144

Table 102: Quarterly Sales Analysis: 2004-2005 (In US$
billion) IV-144

Table 103: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ billion) IV-145

Table 104: Annual Sales Analysis by Product Segment:
2004-2005 (In US$ billion) IV-145

Table 105: Annual Sales Analysis by Geographical
Region: 2004-2005 (In US$ billion) IV-146
37. EMD Biosciences, Inc. (USA) IV-149
38. Endogen, Inc. (USA) IV-155
39. Enzo Diagnostics, Inc. (USA) IV-156
40. Epitomics, Inc. (USA) IV-157
41. Exocell, Inc. (USA) IV-159
42. Fujirebio Diagnostics, Inc. (USA) IV-160
43. Genentech, Inc. (USA) IV-163
Table 106: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-165

Table 107: First Quarter Sales Analysis by Product:
2005-2006 (Q1) (In US$ million) IV-166

Table 108: Annual Sales Analysis: 2003-2005 (In US$
million) IV-166

Table 109: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-166

Table 110: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-166
44. Genzyme Corporation (USA) IV-172
Table 111: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ billion) IV-175

Table 112: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-175

Table 113: Quarterly Sales Analysis: 2004-2005 (In US$
billion) IV-175

Table 114: Annual Sales Analysis by Segment: 2004-2005
(In US$ billion) IV-176

Table 115: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-176
Genzyme Diagnostics (USA) IV-180
Genzyme Virotech GmbH (Germany) IV-181
45. GlaxoSmithKline PLC (UK) IV-182
Table 116: Annual Sales Analysis: 2003-2005 (In Ј
million) IV-183

Table 117: Annual Sales Analysis by Segment: 2004-2005
(In Ј million) IV-183

Table 118: Annual Sales Analysis by Segment: 2003-2004
(In Ј million) IV-183
46. Goodwin Biotechnology, Inc. (USA) IV-191
47. GPC Biotech AG (Germany) IV-193
Table 119: First Quarter Sales Analysis: 2005-2006 (Q1)
(In Ђ million) IV-194

Table 120: Annual Sales Analysis: 2004-2005 (In Ђ
million) IV-194
48. Guildhay Ltd. (UK) IV-195
49. Debiovision Inc IV-196
50. Human Genome Sciences, Inc. (USA) IV-197
Table 121: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-198

Table 122: Annual Sales Analysis: 2003-2005 (In US$
million) IV-198
51. ICOS Corporation (USA) IV-205
Table 123: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ thousands) IV-206

Table 124: Annual Sales Analysis: 2003-2004 (In US$
thousands) IV-206

Table 125: Annual Sales Analysis by Quarter: 2003-2004
(In US$ thousands) IV-206
52. Igen International, Inc. (USA) IV-208
53. Immunodiagnostics, Inc. (USA) IV-208
54. ImmunoGen, Inc. (USA) IV-209
Table 126: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-209

Table 127: Annual Sales Analysis: 2003-2005 (In US$
million) IV-210

Table 128: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-210

Table 129: Annual sales Analysis by Segment: 2004-2005
(In US$ million) IV-210
55. Immunomedics, Inc. (USA) IV-212
Table 130: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ million) IV-212




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com